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Introduction
The skeleton serves to provide structural support to the body, 
allow movement, protect internal organs, regulate calcium 
homeostasis, and provide niches for hematopoiesis. Additionally, 
over the past decade the skeleton has emerged as an important 
endocrine organ, with osteoblast-derived osteocalcin represent-
ing a major player in the regulation of glucose and insulin homeo-
stasis (1, 2). Osteocalcin, in its undercarboxylated form, is released 
as a hormone into the circulation and promotes pancreatic β cell 
proliferation, insulin production, and peripheral insulin sensitivity 
(3). Osteoblasts in turn respond to insulin signaling by increasing 
bone remodeling and the production and bioavailability of under-
carboxylated osteocalcin (4, 5).
Recent reports also implicated osteocalcin-independent 
mechanisms in the bone-metabolism interplay. For example, 
genetically induced ablation of osteoblasts or conditional inacti-
vation of glycogen synthase kinase–3β or β-catenin in osteoblasts 
led to systemic metabolic alterations, which could not be fully 
rescued or explained by congruent changes in serum osteocalcin 
(6–8). These studies indicated that osteoblasts can additionally 
influence global glucose homeostasis and energy metabolism 
through mechanisms that are as yet unknown and that may, or 
may not, be endocrine in nature.
Hypoxia-driven pathways play major roles in pathological con-
ditions such as cancer and metastasis, but are also vital in normal 
development and tissue homeostasis (9). Particularly in the bone 
microenvironment, which is physiologically hypoxic, mechanisms 
regulating cellular adaptation to oxygen-poor conditions are cru-
cial (10). The main orchestrator of the responses to hypoxia is HIF, 
a heterodimer transcription factor comprising a constitutive β sub-
unit (HIF-β) and an oxygen-regulated α subunit (HIF-1α or HIF-
2α). In oxygen-rich conditions, HIF prolyl hydroxylases (PHDs) 
hydroxylate specific residues in the HIF-α protein, rendering it a 
substrate for the E3 ubiquitin ligase von Hippel–Lindau (VHL) and 
a target for proteasomal degradation. When oxygen levels drop 
below a critical level, HIF-α is not hydroxylated and degraded, but 
instead accumulates in the cell, liaises with HIF-β, and induces a 
hypoxia-triggered transcriptional program.
The key HIF target genes help cells face the challenges of low 
tissue oxygen, with 2 major mechanisms standing out. First, HIF-
regulated genes such as VEGF and erythropoietin (EPO) increase 
the tissue oxygen supply by inducing angiogenesis and erythropoi-
esis (9). Genetic studies in mice documented that also in osteoblast 
lineage cells, HIF directly regulates VEGF expression, thereby 
inducing blood vessel growth and bone formation and rendering 
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systemic glucose levels by increasing glucose utilization by the 
skeleton. This simple yet unexpected concept brings a poten-
tial new angle to the sophisticated integration of the skeleton in 
global nutrient homeostasis, and may have broad clinical impact 
with regard to bone and metabolic disorders, as well as in cancer 
pathology and therapy.
Results
Vhl ablation in osteoprogenitors causes increased bone density and 
cortical porosity, along with hypervascularization and alterations in 
the BM environment. To investigate the impact of HIF signaling in 
osteoprogenitors and the osteoblast lineage cells derived thereof, 
Osx(SP7)-Cre:GFP mice (24) were crossed with Vhl floxed mice 
(25). Osx-GFP:CreTG/+ Vhl+/+ mice were used as the control group. 
Genetic targeting of Vhl precludes the oxygen-dependent inacti-
vation of HIF, thus representing a model of constitutive HIF activ-
ity and hypoxia signaling pathway responses, as documented pre-
viously (11, 12, 26).
Vhl conditional knockout (cKO) mice displayed reduced skel-
etal growth (Figure 1A and Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI97794DS1) and a marked high bone mass phenotype at post-
natal stages, characterized by a progressive accumulation of tra-
becular bone even at advanced age, as shown by micro-CT of the 
long bones (Figure 1, B–D). Excessive trabeculae extended far into 
the diaphyseal bone shaft, associated with thinner, highly porous, 
trabecularized cortical bone (Figure 1, B–F). High bone volume 
was also evident in the vertebrae (Figure 1G). Overall, bones in the 
mutant mice were heavier relative to BW than in controls (Supple-
mental Figure 1B). In line with previous reports on comparable 
mouse models (11, 12), Vhl cKO bones showed elevated expression 
of the direct HIF target genes Vegf and Epo (Figure 1H), associated 
with skeletal hypervascularization, BM fibrosis, and splenomegaly 
(Figure 1I and Supplemental Figure 1C).
Inactivation of Vhl in osteoprogenitors leads to an expanded pool 
of early osteolineage cells and a low bone remodeling status in adult 
mice. We further documented the bone remodeling status of the 
mice by analyzing bone formation and osteoblast differentiation 
on the one hand and bone resorption by osteoclasts on the other. 
Static, dynamic, and cellular histomorphometry indicated that by 
12 weeks of age, the high bone mass phenotype was associated with 
substantially decreased active bone formation and mineralization 
activity as determined by calcein labeling (Supplemental Figure 2 
and Figure 2, A and B), along with reduced presence of fully differ-
entiated cuboidal osteoblasts on the bone surfaces of Vhl cKO mice 
compared with controls (Figure 2C). In line therewith, differentia-
tion and mineralization of Vhl-deficient osteoblasts were reduced 
in vitro (Supplemental Figure 3). Expansion of the pool of early 
osteolineage cells in vivo was further supported by the increased 
presence of Osx-expressing cells (Figure 2D), increased expression 
of the early osteogenic cell marker runt-related transcription fac-
tor 2 (Runx2), and strongly decreased expression of the late osteo-
blast and osteocyte markers osteocalcin (Ocn) and sclerostin (Sost) 
(Figure 2E) in bones of Vhl cKO mice. Overall, abundant yet quite 
disorganized collagen and osteoid deposition was observed in the 
mutant bones by sirius red and van Gieson staining (Figure 2, F and 
G). Impaired maturation and turnover of the bone matrix were also 
the hypoxia signaling pathway the first recognized coupler of angio-
genesis and osteogenesis (10, 11). The HIF pathway has also been 
shown to directly regulate EPO expression in osteoblasts, modulat-
ing erythropoiesis in the local hematopoietic BM environment (12).
Second, hypoxia-regulated transcription activates genes and 
pathways that reduce oxygen consumption and the cellular depen-
dence on oxygen, including by mediating a bioenergetic switch 
from oxidative phosphorylation to glycolysis as major route of ATP 
production (9). This shift involves direct HIF-mediated upregula-
tion of glycolytic enzymes such as pyruvate dehydrogenase kinase 
1 (PDK1) and lactate dehydrogenase A (LDHA), promoting the 
conversion of pyruvate into lactate, and of glucose transporters 
(GLUTs, particularly GLUT1) to enhance glucose uptake, thereby 
compensating for the energy inefficiency of glycolysis. A similar 
metabolic reprogramming is also prominent in cancer cells, which 
commonly metabolize glucose by glycolysis even in the presence 
of oxygen, a phenomenon known as the Warburg effect or aero-
bic glycolysis (13, 14). Correspondingly, HIF-induced regulation of 
cellular glucose metabolism is being intensely investigated, with 
promising therapeutic potential in cancer and metastasis (15).
At present, relatively little is known about the metabolic path-
ways and substrates preferentially used by osteoblast lineage cells. 
Moreover, these may change throughout their lifespan and dif-
ferentiation progress, and are likely context dependent (16, 17). 
Recent in vivo work using genetically modified mouse models has 
been actively investigating this topic, and revealed a prominent 
role for glucose metabolism during osteoblast differentiation (18, 
19). Moreover, aerobic glycolysis has been implicated as an impor-
tant driver of bone formation and shown to be regulated by osteo-
anabolic pathways involving Wnt-LRP5 signaling, parathyroid 
hormone, and HIF (20–23).
In this study, we show that the hypoxia signaling pathway 
directs cellular metabolism in osteoblast lineage cells, with HIF-
target gene expression potently stimulating glycolysis and glucose 
consumption. Intriguingly, our findings further indicate that the 
repercussions of this metabolic regulation in osteoblasts extend 
beyond the bone environment, to the control of whole-body ener-
gy metabolism. Specifically, we found that deletion of Vhl in osteo-
progenitors, a model of persistent HIF activation, promoted gly-
colysis and glucose utilization by osteolineage cells. This led to an 
overall increase in glucose uptake from the circulation by the skel-
eton, which in turn correlated with reduced blood glucose levels 
in the mutant mice. The hypoglycemic phenotype was associated 
with an increased glucose tolerance that could not be explained 
through the known endocrine actions of osteocalcin and insulin, 
but which could be pharmacologically rescued by administration 
of a glycolysis inhibitor. This suggests that increased glucose usage 
by osteolineage cells can, possibly directly, stimulate systemic glu-
cose clearance and improve glucose tolerance, and even lead to a 
sustained decrease in the blood glucose levels and to decreased 
peripheral fat accumulation. Strikingly, a parallel was seen with 
cancer patients carrying glucose-avid bone metastases, who also 
showed an inverse correlation between the local glucose uptake in 
the tumor lesions and global blood glucose levels, further under-
scoring the power of the Warburg effect.
Altogether, our findings suggest that hypoxia signaling–
induced excessive glycolysis in osteolineage cells can lower 
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Figure 1. High bone mass and skeletal abnormalities in mice lacking Vhl in osteoblast lineage cells. (A) Tibia length at 12 weeks (n = 4–7 per genotype). 
(B) Representative 3D micro-CT reconstructions of tibias from 12-week-old mice. (C) Bone volume relative to tissue volume (BV/TV, in %) determined by 
micro-CT at the indicated ages (n = 3–5/group). (D and E) Micro-CT analysis of the trabecular (D) and cortical (E) tibia regions at 12 weeks (n = 3–5), showing 
BV/TV; trabecular number (Tb.N), separation (Tb.Sp), and thickness (Tb.Th); and cortical thickness (Cort.Th) and porosity (Cort.Por). (F) Representative 
transverse micro-CT section of the tibia. (G) Vertebral BV/TV determined by micro-CT (n = 4). (H) Relative (Rel.) mRNA levels of Vegf and Epo in full bones 
of 12-week-old mice (n = 7). (I) Tibia histology showing H&E staining, PECAM-1 IHC for blood vessels (including magnifications), and reticulin-positive 
fibers (black stain and yellow arrow) indicative of BM fibrosis in Vhl cKO bones. Scale bars: 500 μm (H&E; PECAM-1 left), 50 μm (PECAM-1 right; reticulin). 
Graphs represent mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test between genotypes.
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(Supplemental Figure 4, A–C). Indirect calorimetry showed nor-
mal food intake, oxygen consumption, and heat production in 
Vhl cKO mice, in the face of a significant decrease in ambulatory 
activity, suggesting that the basal metabolic rate was increased in 
the mutant mice (Figure 3, D and E). Respiratory exchange ratio 
(RER) values were around 0.8 in both genotypes (Figure 3F). 
Serum analysis indicated consistently lower blood glucose levels 
in Vhl cKO mice, both in random-fed and fasted conditions, from 6 
weeks of age onward (Figure 3, G and H, and Supplemental Figure 
4D). The hypoglycemic phenotype was accompanied by enhanced 
clearance of glucose from the blood following i.p. glucose injec-
tion during a glucose tolerance test (GTT), and an overall increase 
in glucose tolerance at the age of 6 weeks (Supplemental Figure 
4E) and 12 weeks (Figure 3I). Likely as a secondary consequence 
of the persistently lower glycemia, the rate-limiting gluconeogen-
esis enzyme phosphoenolpyruvate carboxykinase (PEPCK) was 
upregulated in the liver and muscle of constitutive Vhl cKO mice 
(Figure 3J), suggesting compensatory gluconeogenesis, and glyco-
gen stores were virtually abolished in their livers (Figure 3K).
Unexpectedly, in light of the reduced glycemia and increased 
glucose tolerance, no alterations were observed in the serum insu-
lin levels of Vhl cKO mice compared with controls in random-fed 
or fasted conditions (Figure 3L). Also, the insulin-producing β cell 
area in the pancreas (Supplemental Figure 5) and endogenous insu-
lin secretion in response to glucose injection (glucose-stimulated 
insulin secretion test [GSIS]) (Figure 3M) were normal. Moreover, 
insulin tolerance tests (ITTs) demonstrated a reduction in insulin 
sensitivity in Vhl cKO mice (Figure 3N). Yet, even though Vhl cKO 
mice appeared to be less insulin sensitive than controls, calcula-
tion of the homeostatic model assessment of insulin resistance 
(HOMA-IR) did not classify them as insulin resistant (Figure 3O). 
Furthermore, no evidence was found for peripheral insulin resis-
tance or altered insulin signaling in the liver or skeletal muscle of 
Vhl cKO mice, as indicated by gene expression analysis of insulin 
targets, enzymes involved in carbohydrate metabolism, and mark-
ers of muscle fiber composition (Supplemental Figures 6 and 7), 
and as corroborated by normal glucose uptake in these insulin 
target tissues (Supplemental Figure 6D and see below, Increased 
skeletal glucose uptake correlates with reduced glycemia levels).
Altogether, these data indicate that constitutive skeletal-
targeted Vhl cKO mice have a high bone mass, improved glucose 
metabolism, and a lean body, all in the face of normal food intake 
and reduced physical activity.
Mice with constitutive or induced skeletal Vhl deletion develop 
high bone mass, low glycemia levels, and enhanced systemic glucose 
tolerance, not accounted for by insulin or osteocalcin. As described 
above, constitutive Vhl cKO mice were in a state of persistent low 
glycemia with increased glucose tolerance from juvenile ages 
onward, which appeared to be associated with a failure to build 
up energy stores such as those normally provided by peripheral fat 
and liver glycogen. This observed lipodystrophy/lipoatrophy con-
sequently contributed to the complexity of interpreting the meta-
bolic phenotype in this constitutive model. Therefore, we addi-
tionally generated a postnatally induced Vhl cKO (PN–Vhl cKO) 
mouse model, by preventing the recombination of the floxed Vhl 
gene during development and until postnatal week 3 through the 
administration of doxycycline, which silences the tetracycline-off 
indicated by safranin O staining, which revealed abundant rem-
nants of cartilage matrix within the trabecular bone structures of 
Vhl cKO mice, extending abnormally deep into the diaphysis (Fig-
ure 2H). While sustained cartilage remnants are generally indica-
tive of reduced resorptive activity, we could not detect significant 
alterations in the number of osteoclasts (Figure 2, I and J) or in 
the expression levels of osteoclast-specific marker genes such as 
Rank and cathepsin K (CathK), in Vhl cKO bones (Figure 2K). The 
expression levels of Rankl and osteoprotegerin (Opg), prime regu-
lators of osteoclastogenesis expressed by osteoblast lineage cells, 
were both significantly increased in Vhl cKO bones compared with 
controls, yet the overall Rankl/Opg ratio remained indifferent (Fig-
ure 2K). Last, the serum procollagen type 1 N-terminal propeptide 
(P1NP) and C-terminal telopeptide (CTX) levels, respective mark-
ers of bone formation and resorption, were not significantly altered 
in Vhl cKO versus control mice at 12 weeks of age; however, when 
corrected for trabecular bone perimeter, both parameters were sig-
nificantly decreased in the mutant mice (Figure 2, L and M), in line 
with the overall presumption of a relatively low bone turnover sta-
tus in adult Vhl cKO mice.
Vhl cKO mice are lean, despite reduced physical activity, and 
display hypoglycemia and increased glucose tolerance. Surprisingly, 
constitutive deletion of VHL in osteoprogenitors was associated 
with distinct alterations in whole-body homeostatic processes. 
Vhl cKO mice showed markedly low BWs compared with litter-
mate control mice from 3 weeks of age onward, and they appeared 
to be resistant to age-related weight gain, with the deviation in 
BW between the genotypes increasing throughout postnatal life 
(Figure 3A). The mutant mice had a lean appearance, displaying 
greatly reduced abdominal and subcutaneous fat (Figure 3, B and 
C), associated with reduced circulating levels of leptin but with-
out changes in circulating adiponectin or in serum triglycerides 
Figure 2. Inactivation of Vhl in osteoprogenitors leads to an expanded 
pool of early osteolineage cells and a low bone turnover status in adult 
mice. (A) BV/TV (%) as quantified on von Kossa–stained sections (n = 8). 
(B) Mineral apposition rate (MAR) and bone formation rate corrected for 
bone surface (BFR/BS) quantified in mice injected with calcein twice with 
a 3-day interval (n = 3–7). (C) Numbers of mature, cuboidal osteoblasts 
located on the bone trabecular surface, expressed as absolute numbers 
(N.Ob in the region of interest, per unit of tissue area [T.Ar], left) or relative 
to bone perimeter (N.Ob/B.Pm, right) (n = 7–8). (D) Co-IHC for PECAM-1 
and GFP (left) and number of Osx-Cre:GFP+ cells (right) (n = 5). Scale bar: 
50 μm. (E) mRNA levels of the osteoblastogenesis markers Runx2, Osx, 
dentin matrix acidic phosphoprotein 1 (Dmp1), Ocn, and Sost (n = 7–8). 
(F) Representative sirius red–stained sections showing collagen fibers 
dispersed in the inter-trabecular BM environment (arrows) in mutant 
mice (n = 3). Scale bars: 100 μm. (G) von Kossa/van Gieson staining (n = 
4), revealing mineralized bone (black) and nonmineralized osteoid (red, 
arrows). Scale bars: 50 μm. (H) Safranin O staining (n = 5). Scale bars: 50 
μm. (I) Tartrate-resistant acid phosphatase (TRAP) staining for osteoclasts 
(red, see magnification in inset) (n = 6–8). Scale bars: 200 μm. (J) Number 
of TRAP+ osteoclasts (N.Oc) in absolute terms per T.Ar (left) and relative to 
B.Pm (right) (n = 6–8). (K) mRNA expression of osteoclast-specific markers 
(Rank, CathK) and osteoclastogenesis regulators (RankL, Opg) (n = 7). (L) 
Serum CTX values, expressed in absolute terms (left, n = 13–18) or cor-
rected for B.Pm (right, n = 5–7). (M) Serum P1NP values, in absolute terms 
(left, n = 11–18) and corrected for B.Pm (right, n = 3–6). Graphs represent 
mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test 
between genotypes.
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system–containing (Tet-Off–containing) Osx-Cre:GFP transgene 
(24) (Figure 4A). In contrast to the constitutive Vhl cKO mouse, 
the induced mutant PN–Vhl cKO mice appeared neither smaller 
nor leaner than control littermates, as evidenced by their normal 
BW and abdominal fat accumulation (Figure 4, B and C). Circu-
lating levels of adiponectin were also unchanged in PN–Vhl cKO 
mice (Figure 4D), and their livers showed no alterations in mRNA 
expression levels of genes involved in glycolysis, gluconeogenesis 
(Pepck), and glycogen metabolism (Supplemental Figure 7). Inter-
estingly though, from the age of 12 weeks and most evidently by 24 
weeks, the PN–Vhl cKO mice recapitulated all other key features of 
the constitutive Vhl cKO model, as they displayed a marked high 
bone mass (Figure 4, E–H), reduced fasted blood glucose levels 
(Figure 4I), and increased glucose tolerance (Figure 4J) compared 
with control littermates, without alterations in serum insulin lev-
els (Figure 4K) or insulin sensitivity (Figure 4L). This phenotype 
was documented in both male and female groups of mice (Figure 
4 and Supplemental Figure 8). As in the constitutive model, the 
local alterations in the bones of PN–Vhl cKO mice were associated 
with increased expression of Vegf and Epo, skeletal hypervascu-
larization, and splenomegaly (Supplemental Figure 9). Indirect 
calorimetry showed normal oxygen consumption, heat produc-
tion, and ambulatory activity, but a significant increase in RER in 
the PN–Vhl cKO mutants, suggesting a slightly increased glucose 
metabolism (Supplemental Figure 10).
These data show that the local and systemic repercussions of 
constitutive Vhl deletion in osteolineage cells were recapitulated in 
a context of normal development and baseline physiology using a 
postnatal inducible genetic system. The PN–Vhl cKO mouse there-
by provided an additional and simplified model to explore the role 
of the skeleton in the regulation of global glucose homeostasis.
Since these findings underscored a novel potential link 
between hypoxia pathway signaling in osteolineage cells and 
whole-body energy metabolism, we thoroughly checked the skel-
etal specificity of the genetic targeting strategy. The history of 
the Osx-Cre:GFP–mediated recombination was evaluated in sec-
tions of bone and soft tissues using the IRG transgenic reporter 
mouse, in which cells switch from red fluorescent protein to GFP 
expression following Cre-mediated recombination. As expected, 
the reporter readout in bone revealed Osx-Cre–targeted GFP+ 
cells in the hypertrophic chondrocyte regions of the growth plate, 
throughout the metaphysis and in the cortical and trabecular bone 
areas (Supplemental Figure 11A). The GFP signal corresponded 
with osteolineage cells on the bone surfaces as well as some GFP+ 
reticular cells dispersed within the BM stroma (Supplemental Fig-
ure 11A, middle) and the majority of bone-embedded osteocytes 
(Supplemental Figure 11A, bottom). Abundant Osx-Cre–targeted 
cells and progeny were observed in bones from Vhl cKO mice (Sup-
plemental Figure 11B). When evaluating the IRG reporter readout 
of Osx-Cre activity in other tissues, including the spleen, liver, 
and intestine, we did not observe any GFP+ cells (Supplemental 
Figure 11C). Furthermore, we quantified the mRNA levels of Vhl 
and a panel of highly responsive HIF target genes (phosphoglycer-
ate kinase 1 [Pgk1], Epo, Glut1, and Vegf) in brain, liver, pancreas, 
and small intestine of control and constitutive Vhl cKO mice. No 
detectable upregulation was seen for any of these genes in the soft 
tissues derived from the mutant mice (Supplemental Figure 12A), 
whereas they all showed very strong upregulation in Vhl-deficient 
osteoblasts and in bones derived from Vhl cKO mice (Supple-
mental Figure 12, B and C). The sensitivity of this approach and 
significance of this finding is underscored by the fact that these 
whole-bone samples contain only around 2%–2.5% osteolineage 
cells, with the majority of the sample representing the nontargeted 
hematopoietic cells of the BM (data not shown). When the Osx-
Cre:GFP+ cells were selectively sorted from calvaria or long bones 
of control and Vhl cKO mice by FACS, they revealed effective inac-
tivation of the Vhl gene. As shown in Supplemental Figure 12D, Vhl 
mRNA levels were reduced (by up to 80%) specifically in the Osx-
Cre:GFP+ cell fractions derived from mutant mice and not in the 
Osx-Cre:GFP– cell fractions. Altogether these data indicate that Vhl 
recombination was efficient in the osteolineage cells of bone, but 
absent or marginal in the nonskeletal tissues tested.
Given that osteoblast-derived osteocalcin is the principal 
known mediator of the interplay between bone and energy metab-
olism, we next quantified the osteocalcin protein levels in the 
serum of mice with constitutive or induced conditional Vhl dele-
tion. Interestingly, circulating osteocalcin levels were strongly 
reduced (up to 80%) in Vhl mutant mice compared with controls 
(Figure 5, A and B), corresponding to the low bone remodeling sta-
tus of the mice (see Figure 2). These low serum osteocalcin levels 
were in line with the substantial downregulation of Ocn mRNA 
expression in bones of Vhl cKO and PN–Vhl cKO mice (Figure 5, 
C and D) and with reduced Ocn mRNA expression in Vhl-deficient 
primary osteoblasts (Figure 5E). However, these results were 
unpredicted in light of the hypoglycemic phenotype, since serum 
osteocalcin levels generally inversely relate to plasma glucose (3).
Altogether, our data indicate that skeletal-targeted Vhl cKO 
mice, both the constitutive and the postnatally induced models, 
showed a high-bone-mass phenotype locally and low glycemia 
with increased glucose tolerance systemically. Intriguingly, the 
low glycemia and increased glucose tolerance in Vhl cKO mice 
could not be simply explained through increased insulin or osteo-
Figure 3. Osteoprogenitor-targeted Vhl cKO mice are lean, despite normal 
food intake and reduced physical activity, and display a hypoglycemic 
phenotype with increased systemic glucose tolerance. (A) BW of control 
and constitutive Vhl cKO mice at the indicated ages (n = 3–10/group). (B) 
Abdominal fat mass as absolute values, in grams (left), and relative as per-
centage of BW (right) (n = 10–14) in 12-week-old male mice. (C) Representa-
tive H&E-stained skin sections. Scale bar: 100 μm. Arrows point to subcu-
taneous fat. (D) Food intake over 2 days/nights, in absolute values (left) 
and corrected for the metabolic BW (BW0.75, BW raised to the three-quarter 
power, as commonly used to normalize energy metabolism data) (right) 
(n = 6–7). (E) Indirect calorimetry measurements of oxygen consumption, 
heat production, and ambulatory activity, corrected for BW0.75 (n = 6–7). (F) 
RER (n = 6–7). (G) Blood glucose levels in random-fed state from P1.5 to 
P42 (n = 6–8/group). (H) Blood glucose levels after overnight fasting at 12 
weeks (n = 7–9). (I) GTT and its quantification as AUC (n = 7–9). (J) Pepck 
mRNA levels in liver and muscle (n = 4). (K) PAS staining on liver, revealing 
glycogen content (n = 4). Scale bar: 100 μm. (L) Serum insulin levels in 
random-fed (left) and fasted (right) conditions (n = 4–9). (M) GSIS (n = 9). 
conc, concentration. (N) ITT and AUC quantification (n = 6–9). (O) HOMA-IR 
(n = 9). All analyses were performed on male control and constitutive Vhl 
cKO mice at 12 weeks of age, unless indicated otherwise. Graphs represent 
mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test 
between genotypes, unless indicated otherwise.
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Figure 4. PN–Vhl cKO mice recapitulate the key skeletal and systemic features of the constitutive Vhl cKO model while showing normal BW and fat 
mass. (A) Scheme of doxycyclin administration to silence Osx-Cre:GFP activity from conception until weaning. (B) BW of control and PN–Vhl cKO mice at 
the indicated ages (n = 6–9). (C) Abdominal fat weight as percentage of BW at 24 weeks (n = 6–7). (D) Serum adiponectin levels at 24 weeks (n = 7–8). (E) 
Relative BV/TV change over time analyzed by in vivo micro-CT. (F and G) Bone mineral density (BMD) (F) and BV/TV (%) (G) determined by ex vivo micro-CT 
at 24 weeks (n = 7–8). (H) Representative sirius red–stained tibia sections (scale bars: 500 μm) (n = 3). (I) Blood glucose levels at 3 weeks of age (overnight 
fast, n = 6), 12 weeks (overnight fast, n = 6–8), 15 weeks (3-hour fast, n = 6–8), and 24 weeks of age (overnight fast, n = 7–8). (J) GTT at 12 weeks (n = 3–7) 
and 24 weeks (n = 7–8), with corresponding AUC calculations. (K) Serum insulin levels in random-fed conditions at 24 weeks in females (left, n = 4–5) and 
males (right, n = 7). (L) ITT and corresponding AUC (n = 4–5). Graphs represent mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test 
between genotypes, unless indicated otherwise. All data in B–J and L were obtained in male control and induced PN–Vhl cKO mice. Corresponding data 
from female groups are shown in Supplemental Figure 8.
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cells were normal (Figure 6K), as was the phosphorylation status 
of the cellular energy sensor AMPK (Figure 6L).
These data provide evidence that the uptake and energy-
inefficient glycolytic breakdown of glucose is greatly increased 
in Vhl-deficient osteoblasts, to the extent that their reduced 
mitochondrial respiration is compensated for and cellular energy 
homeostasis is maintained.
Osteoblast lineage cells are prime glucose-consuming cells in the 
bone environment. The molecular alterations observed in vitro 
were confirmed in vivo: bones of Vhl cKO and PN–Vhl cKO mice 
displayed increased mRNA expression of key glycolytic enzymes, 
most pronouncedly Pgk1 and Pdk1, and of Glut1 (Figure 7, A and 
B). Immunostaining confirmed an increased presence of GLUT1 
in the mutant bones of both the constitutive and the postnatally 
induced models, particularly in osteoblast lineage cells on and 
around the bone surfaces (Figure 7, C and D). To visualize the 
uptake of glucose in situ, we next administered 2-NBDG to con-
trol and Vhl cKO mice, and assessed the uptake and accumulation 
of the compound in the tibia and calvaria, harvested 5 minutes 
(data not shown) or 45 minutes (Figure 7E and Supplemental Fig-
ure 13, A and B) after the injection. These experiments revealed 
that osteoblasts lining the bone surfaces take up glucose quickly 
and abundantly, and represent by far the most glucose-avid cells 
in mouse bones, with relatively sparse uptake being detected in 
chondrocytes, hematopoietic cells, and osteocytes (Figure 7E, 
upper panels and Supplemental Figure 13A). The major glucose-
consuming cells included presumed immature osteogenic cells in 
the primary spongiosa (close to the growth plate) and in the tra-
becular bone microenvironment, flattened bone lining cells, and 
cuboidal mature osteoblasts on the trabeculae and on the cortical 
bone, which were overall particularly abundant in the mutant mice 
(Figure 7E, bottom panels).
These data suggest that osteoblast lineage cells, in particular 
osteoprogenitors and osteoblasts, are responsible for a substantial 
part of the skeletal glucose uptake. Alterations in their glucose uti-
lization may consequently impact notably on the skeleton’s overall 
glucose consumption. The increase in glycolytic pathway activation 
calcin signaling, indicating that an alternative mechanism must 
underlie the phenotype.
Excessive glucose uptake and glycolysis in Vhl-deficient osteo-
blasts. In search of the mechanism underlying the systemic phe-
notype of the Vhl cKO mice, we reverted to the primary target 
of our genetic strategy, the osteoblast, and used Vhlfl/fl primary 
osteoblasts transduced in vitro with adenoviruses expressing Cre 
(AdCre) or carrying a control vector (AdEmpty/AdGFP) as a mod-
el system. The AdCre-treated cells showed over 90% downregu-
lated Vhl mRNA levels and effective HIF-1α protein stabilization 
(Figure 6, A and B).
Consistent with the presence of consensus hypoxia-response 
elements (HREs, the recognition sites for HIF) in their regulatory 
sequences, the genes encoding the glycolysis-regulating enzymes 
PGK1, PDK1, and LDHA were significantly upregulated in Vhl-
deficient cells (Figure 6C). AdCre cells also displayed elevated 
expression of several GLUTs (Figure 6D), particularly GLUT1, 
the dominant glucose transporter in osteoblasts (18). In line with 
these changes at the gene expression level, Vhl-deficient cells 
showed increased uptake of glucose and production of lactate, 
as documented by analysis of conditioned culture media (Figure 
6E) and quantification of cellular uptake of 2-NBDG, a fluores-
cently labeled glucose analog (Figure 6F) that is not metabolized. 
Extracellular flux analysis confirmed that the mutant cells dis-
played a change in their bioenergetics, as evidenced by increased 
extracellular acidification rates (ECARs) (Figure 6G), reflecting 
the strongly increased lactic acid secretion, and decreased basal 
oxygen consumption rates (OCRs) (Figure 6H), indicative of 
reduced glucose oxidation. The response of AdCre-treated cells 
to mitochondrial stress test components (oligomycin, FCCP, and 
rotenone) indicated trends toward reduced oxygen consumption 
for ATP production (P = 0.065) and maximum respiration capac-
ity (Figure 6I), yet no significant differences were seen in these 
circumstances. In line with these results, we documented slightly 
downregulated expression of mitochondrial biogenesis markers in 
Vhl-deficient cells (Figure 6J). Yet, despite the lowered mitochon-
drial respiration, the levels of ATP produced by AdCre-treated 
Figure 5. Vhl-deficient mice develop increased glucose tolerance 
and low glycemia despite greatly reduced production and levels of 
osteocalcin in their bones and serum. (A and B) Serum osteocalcin 
(Ocn) levels in (A) control and constitutive Vhl cKO mice (n = 9–14) 
and (B) control and PN–Vhl cKO mice (n = 7–8.). (C and D) Ocn mRNA 
levels in bones of (C) 12-week-old control and constitutive Vhl cKO 
mice (n = 7) and (D) 24-week-old control and PN–Vhl cKO mice (n = 
6–8). (E) Ocn mRNA levels in osteoblasts derived from Vhl-floxed 
mice and transduced with AdEmpty or AdCre in vitro (also see Fig-
ure 6) (n = 5). All data were obtained in male mice. Graphs represent 
mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s  
t test between genotypes, unless indicated otherwise.
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next performed micro-PET scans and biodistribution assays using 
the radioactive tracer 18F-fluorodeoxyglucose (18F-FDG). In normal 
adult mice, the skeleton was found to take up a considerable por-
tion of the injected glucose (14.7% of retrieved dose) relative to glu-
caused by Vhl deficiency in osteolineage cells in vivo may therefore 
affect total glucose uptake in the bones of the mutant mice.
Increased skeletal glucose uptake correlates with reduced glycemia 
levels. To quantify the glucose consumption by the skeleton, we 
Figure 6. Vhl-deficient osteoblasts show increased glucose uptake and glycolysis. (A) Relative mRNA expression levels of Vhl in cultured primary osteo-
blasts derived from Vhlfl/fl mice and transduced with adenoviruses expressing GFP (AdGFP) or Cre (AdCre) (n = 5 paired independent cell pools). (B) Western 
blot for HIF-1α confirming its effective stabilization in Vhl-deficient cells (AdCre) compared with control cultures (AdGFP) (n = 3). (C and D) mRNA levels of 
(C) Pgk1, Pdk1, hexokinase 2 (HkII), and Ldha, and (D) Glut1–4 in AdGFP- versus AdCre-transduced Vhlfl/fl osteoblasts (n = 5 cell pools). (E) Glucose (left) and 
lactate (right) concentration in unconditioned (black bars) and 24-hour-conditioned medium (n = 5–6). med., medium. (F) 2-NBDG uptake in primary osteo-
blasts (normalized for DNA content of the well, n = 3). (G–I) Extracellular flux analysis of primary osteoblasts (n = 5), showing (G) ECAR, (H) basal oxygen 
consumption, and (I) OCR during a mitochondrial stress test including the oxygen consumption needed for ATP production and at maximum respiration, 
all normalized for DNA content. (J) Relative mRNA expression levels of mitochondrial biogenesis genes in control (AdGFP) versus Vhl-deficient (AdCre) 
cultured osteoblasts (n = 5), showing peroxisome proliferator–activated receptor γ coactivator 1α (Pgc1α), transcription factor A, mitochondrial (Tfam), 
transcription factor B1, mitochondrial (Tfbm1), nuclear respiratory factor 1 (Nrf1) and 2 (Nrf2). (K) ATP production, normalized for DNA (n = 4). (L) Western 
blot for phosphorylated and total AMPK, showing representative results of n = 3 paired independent cell pools (AdGFP, AdCre) and quantification of the 
signal in n = 6 pools. Graphs represent mean ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test between genotypes.
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ing to the regions of intense population by glucose-avid osteoblasts 
(see Figure 7, C–E). Three-compartment model kinetic analyses 
further substantiated the increased 18F-FDG uptake in the mutant 
bones (Supplemental Figure 13C). In contrast to the skeleton, which 
represents the targeted organ in this Osx-Cre:GFP–driven genetic 
strategy, the liver showed no differences in 18F-FDG uptake between 
the genotypes (Figure 8, B and F). Most interestingly, we found that 
the 18F-FDG uptake values in the bones of individual mice negative-
ly correlated with the animal’s glycemic levels (Figure 8G), whereas 
such correlation was not seen in the liver (Figure 8H).
cose storage tissues and high energy–demanding organs (e.g., liver 
7.4%, brain 6.3%, heart 11.7%) (Figure 8A). Strikingly, the uptake 
of glucose was significantly and consistently increased in bones 
(except forelimbs) of Vhl cKO mice compared with control animals, 
as shown by tissue-specific quantification of the 18F-FDG uptake 
(Figure 8B and Supplemental Table 1 showing soft tissues) and by 
micro-PET images analyzed over a 60-minute time frame (Figure 
8, C–E). Time-activity curves of 18F-FDG uptake revealed increased 
accumulation of the glucose analog in the metaphyseal regions of 
the tibias and femurs of Vhl cKO mice (Figure 8, C–E), correspond-
Figure 7. Osteoblast lineage cells are the prime glucose-consuming cells in the skeleton. (A) Relative mRNA levels of Pgk1, Pdk1, HkII, Ldha (left), and 
Glut1–4 (right) in bones of 12-week-old control and constitutive Vhl cKO mice (n = 7). (B) mRNA levels of Pgk1 and Glut1 in bones of control and PN–Vhl cKO 
mice at 24 weeks (n = 6–8). (C and D) GLUT-1 IHC on tibia sections of (C) Vhl cKO mice (scale bars: 200 μm [top] and 25 μm [bottom, magnified views]) and 
(D) PN–Vhl cKO mice (scale bars: 500 μm [top] and 100 μm [bottom, magnified views]). (E) Visualization of 2-NBDG uptake in tibias harvested 45 minutes 
after injection; the signal is strongest in the metaphyseal (meta), trabecular (trab), and cortical (cort) bone regions (most evidently localizing in osteolin-
eage cells on and around the bone surfaces [arrows]), and less intense in growth plate (gp) chondrocytes, BM hematopoietic cells, and bone-embedded 
osteocytes. Scale bars: 50 μm. Data are shown as mean ± SEM; *P < 0.05, ***P < 0.001 by Student’s t test. C–E show representative sections of n = 3 mice 
analyzed per genotype.
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the level of glucose uptake in the metastatic lesions (calculated as 
average maximum and mean 18F-FDG standardized uptake values 
[SUVs]) inversely correlated with the blood glucose levels and gly-
cated hemoglobin values (Hba1C, a measure of the 3-month aver-
age plasma glucose concentration) (Figure 9 and Supplemental 
Table 3). By contrast, no correlation was found between SUV indices 
and insulin, HOMA-IR, or HOMA-β (denoting β cell functioning), 
or between blood glucose or HbA1c and total osteocalcin or bone 
resorption, assessed by serum CTX (Supplemental Table 3).
These data support the concept that metabolic rewiring 
resulting in excessive glucose utilization by a selective subset of 
cells can effectively impact blood glucose levels, and additionally 
underscore the potential broad-ranging implications and clinical 
significance of our findings.
These findings suggested that manifest uptake of glucose by 
a selected subset of cells primed toward excessive (HIF-driven) 
glycolysis, in this case osteoblasts, was able to affect global glu-
cose homeostasis. We next sought to test the conceptual basis of 
this hypothesis in an independent model and a human setting. 
Increased glycolysis through activation of the Warburg effect (often 
even HIF-induced) is a hallmark of malignant cells; moreover, the 
selective high uptake of glucose by tumor cells forms the basis of 
the diagnostic use of 18F-FDG PET/CT scans for clinical detection 
of cancer and metastases (15). In questioning whether the activ-
ity of glucose-avid tumor cells may be linked to serum glycemia, 
we analyzed the 18F-FDG PET/CT scans of 10 patients with lung 
adenocarcinomas (presented in Supplemental Table 2) displaying 
metastatic cancer lesions in one or several bones (27). Interestingly, 
Figure 8. Increased uptake of glucose in 
bones of Vhl cKO mice inversely correlates 
with their blood glucose levels. (A) Uptake 
of 18F-FDG in organs harvested from control 
mice 45 minutes after i.v. injection, expressed 
as percentage of the total documented 
uptake (retrieved activity) in the respective 
individual animals. Mean ± SEM, n = 14. (B) 
Uptake of 18F-FDG in the liver and various 
bones of control and Vhl cKO mice at 12 
weeks, calculated as percentage of the total 
retrieved activity in the respective animal 
and expressed relative to the controls (n 
= 4–7). (C) Time-lapse imaging of 18F-FDG 
uptake by micro-PET (n = 6–7), showing for 
each genotype the coronal slice selected for 
highest 18F-FDG intensity at the level of the 
tibia (asterisk) (left image), the sagittal slice 
displaying the highest intensity signal in 
the vertebral column (arrow) (upper right), 
and a coronal maximum intensity projec-
tion of the hind limb (HL) (lower right). FL, 
forelimb. (D–F) Kinetic analyses of micro-PET 
scans over a 60-minute time frame (n = 6–7), 
showing the quantified plateau activity in 
the distal femur and proximal tibia (D) and 
kinetic analyses over the full time frame in 
these bone regions (E) and in the liver (F). 
(G and H) Analysis of correlation between gly-
cemia level and relative 18F-FDG uptake (at 45 
minutes) in bone (G) or in liver (H). Individual 
data points of control (black dots) and Vhl 
cKO (red dots) mice are shown, and P value 
and Pearson correlation coefficient (r) values; 
total n = 36. Graphs represent mean ± SEM, 
and *P < 0.05, **P < 0.01, ***P < 0.001 by 
Student’s t test between genotypes, unless 
indicated otherwise.
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a consequence of the partial obliteration of the BM cavity by the 
excessive bone matrix, PN–Vhl cKO mice showed splenomegaly 
regardless of the DCA treatment, as documented in both male and 
female animals (Figure 10G).
These data indicate that pharmacological inhibition of gly-
colysis by DCA, a compound shown to correct the increased glu-
cose utilization by Vhl-deficient osteoblasts, was able to prevent 
the global metabolic phenotype of the skeletal-targeted Vhl cKO 
mice and uncouple it from the high bone mass. Although DCA 
was systemically administered, these findings strongly suggest 
a link between the metabolic rewiring of the mutant osteoblasts 
toward excessive glycolysis, so-called hyper-Warburgism, and the 
systemic phenotype of altered glucose homeostasis and energy 
metabolism (Figure 11).
Discussion
The data presented here provide genetic and pharmacological 
support for the concept that the cellular metabolism of the osteo-
blast and the level of glucose consumption in bone might have 
repercussions on global glucose clearance and energy homeo-
stasis (Figure 11). These results implicate the hypoxia signaling 
pathway and local (HIF-driven) glycolysis in the bone-metabolism 
interplay, and extend our insight into the skeletal contribution to 
the regulation of integrated, whole-body homeostatic balances.
Hypoglycemia and increased glucose tolerance in skeletal-targeted 
Vhl mutant mice. While previous studies have shown that activa-
tion of the HIF pathway in osteolineage cells is anabolic to bone, 
to our knowledge no study has previously reported a systemic 
metabolic phenotype in Osx-Cre–driven Vhl cKO mice or in a com-
parable mouse model. Yet intriguingly, both the constitutive and 
the postnatally induced skeletal-targeted Vhl cKO mice generated 
here displayed not only a high bone mass, but also a marked whole-
body phenotype characterized by permanently low glycemia lev-
els and increased glucose tolerance. In the constitutive model, 
the inactivation of Vhl early in life led to an increased metabolic 
rate and failure to build up energy stores, causing a lean appear-
ance with a marked deficiency in body fat. This lipodystrophy or 
lipoatrophy may plausibly explain the mildly reduced sensitivity 
to insulin of the constitutive Vhl cKO mice; alternatively, it could 
represent an adaptive response to the permanently low blood glu-
cose levels, in order to prevent hypoglycemic death. Of note, the 
reduced BW of the constitutive Vhl cKO mice was already evident 
at postnatal week 3, the time at which doxycycline was only begin-
ning to be washed out of the system in the PN–Vhl cKO model. 
The postponement of Vhl deletion in the Osx-expressing target 
cell population until 3 weeks of age successfully avoided much of 
Increased glycolysis in Vhl-deficient osteoblast lineage cells can 
affect systemic glucose homeostasis. The results described above 
raised the hypothesis that increased glycolysis in osteoblast lin-
eage cells could, possibly directly, lower blood glucose levels and 
cause disturbances in whole-body glucose homeostasis. If this 
hypothesis is correct, then pharmacological restoration of the 
reprogrammed cellular metabolism by administration of a glycol-
ysis inhibitor would be expected to prevent the systemic glucose 
sensitivity in Vhl cKO mice. To test this, we used dichloroacetate 
(DCA), a compound whose therapeutic benefits against cancer 
are being tested in clinical trials (15). DCA inhibits glycolysis by 
inhibiting PDK1, an enzyme that inhibits pyruvate dehydrogenase 
and thereby the flux of pyruvate into the mitochondria and the 
tricarboxylic acid cycle (Supplemental Figure 14A). HIF-1 directly 
and potently induces Pdk1 expression in hypoxic cancer cells and 
conceivably also in our Vhl-deficient osteoblasts (Figure 6C and 
Figure 7A), thereby promoting the conversion of pyruvate into lac-
tate in the cytosol.
Administration of DCA to control (AdEmpty) and Vhl-defi-
cient (AdCre) osteoblasts indeed restored the increased glycolysis 
(reflected in the ECARs) and the reduced oxidative respiration (as 
based on the OCRs) of the mutant cells to the baseline control lev-
els (Figure 10A and Supplemental Figure 14B). Consequently, the 
increased glucose utilization of cells lacking Vhl was diminished 
by DCA in a dose-dependent manner (Supplemental Figure 14C). 
Next, we tested the effect of DCA in vivo (Figure 10B). Interest-
ingly, administration of DCA to PN–Vhl cKO mice prevented the 
development of the deregulated whole-body glucose metabolism. 
Specifically, DCA treatment corrected the lower fasted blood 
glucose levels of PN–Vhl cKO mice (Figure 10C) as well as their 
increased glucose tolerance (Figure 10D), rendering DCA-treated 
PN–Vhl cKO mice globally indistinguishable from their age- and 
sex-matched control littermates (either vehicle- or DCA-treated). 
No alterations were observed among any of the groups in BW 
over time or in abdominal fat weight (data not shown). Similar 
data were obtained in female (Figure 10, C and D) and male (not 
shown) groups of mice.
In contrast to the rescued systemic metabolic phenotype, 
bone analyses by micro-CT and histology revealed that the devel-
opment of the high-bone-mass phenotype in PN–Vhl cKO mice 
remained unaffected by DCA treatment (Figure 10E and Sup-
plemental Figure 14D). Increased expression of the HIF-target 
genes Vegf and Epo in bones with conditional Vhl deficiency was 
also maintained upon DCA treatment (Figure 10F), as were the 
pronounced local alterations in the bone environment, including 
the hypervascularization (Supplemental Figure 14D). Likely as 
Figure 9. Higher glucose uptake values in glucose-
avid tumor metastases correlate with lower glyce-
mia levels in a cohort of patients with lung adeno-
carcinoma with bone metastases. (A and B) Analysis 
of correlation between average maximum 18F-FDG 
SUVs (SUV Max Avg) in bone metastases of individual 
patients with cancer, and their fasted glycemia levels 
(A) or glycated hemoglobin (HbA1c) levels (B). Indi-
vidual patient data points and P value and Spearman 
correlation coefficient (r) are shown; n = 10.
Downloaded from http://www.jci.org on February 12, 2018.   https://doi.org/10.1172/JCI97794
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 4 jci.org
which provided us with a simplified and supportive additional 
model for dissecting how genetic, molecular, and cellular changes 
in the bone environment can affect systemic glucose metabolism.
Initially, we hypothesized that osteocalcin may have been 
involved in integrating the skeletal mutagenesis with the global 
repercussions on glucose homeostasis and energy metabolism. 
However, the unexpectedly low production and strikingly low cir-
culating levels of osteocalcin in the Vhl-deficiency models (that 
reflect impaired terminal osteoblast differentiation and low bone 
turnover, as discussed below) are not in correspondence with a 
dominant role for osteocalcin signaling in the systemic phenotype 
of our mice. The serum levels of osteocalcin (total and undercar-
boxylated forms) are generally inversely related to plasma glu-
cose, fat mass, and the degree of insulin resistance in mice and 
the potentially confounding phenomena in key endocrine periph-
eral tissues that contributed to the complexity of the constitutive 
model (such as the fat deficiency); thus, the PN–Vhl cKO mouse 
recapitulated the key features of low glycemia and increased glu-
cose tolerance in a context of normal development, early postna-
tal growth, and baseline physiology. We presume that, by the time 
of pervasive Vhl deletion in the skeleton, the PN–Vhl cKO mice 
were already relatively resilient to some of the systemic effects 
of increased glucose uptake by the mutant osteolineage cells, and 
that their bodies were better furnished than those of the constitu-
tive Vhl cKO mice to respond to these changes and safeguard some 
of the homeostatic balances. The PN–Vhl cKO model may thereby 
be viewed as a model of reduced stringency on the system (hypo-
morph) compared with the effects of constitutive skeletal Vhl loss, 
Figure 10. Pharmacological inhibition of glycolysis by DCA specifically prevents the global metabolic phenotype of mice with skeletal Vhl deficiency. 
(A) ECAR in control (AdEmpty) and Vhl-deficient (AdCre) primary osteoblasts, measured over time (left) and averaged (right) in basal conditions or follow-
ing administration of DCA at the indicated time (n = 7). Data represent mean ± SEM; *P < 0.05; Student’s t test between pairs. (B) Protocol outlining the 
administration of the PDK1 inhibitor DCA from weeks 3 to 24 of postnatal life of control and PN–Vhl cKO mice, in which Vhl inactivation was postponed 
by suppressing Osx-Cre:GFP activity with doxycycline. (C) Fasting glucose levels (2-way ANOVA, P < 0.05 for interaction between genotype and DCA treat-
ment and *P < 0.05 between control and PN–Vhl cKO mice in vehicle group by Bonferroni’s post test; n = 5–6). (D) GTT (*P < 0.05; multiple Student’s t 
tests between time points) and corresponding AUC calculations (2-way ANOVA, P < 0.05 for interaction between genotype and DCA treatment and *P < 
0.05 between control and PN–Vhl cKO mice in vehicle group by Bonferroni’s post test; n = 5–6). (E) Tibia BV/TV determined by ex vivo micro-CT in male  
(n = 6–8; blue bars) and female (n = 4–5; red bars) mice. (F) Vegf and Epo mRNA levels in full bones (n = 7–9 mice/group). (G) Spleen weight as percentage 
of BW at 24 weeks in male (n = 6–7) and female (n = 5) mice. In E–G, graphs represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001; 2-way ANOVA with 
Bonferroni’s post test. Blue graphs, male data; red graphs, female data.
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ings support the notion that osteolineage cells can impact global 
energy metabolism through other as-yet-uncharacterized mecha-
nisms, as suggested previously (6–8).
Cellular glucose utilization by osteoblasts as a determinant of 
global energy homeostasis. Intriguingly, while the low blood glucose 
levels in Vhl-depleted mice could not be explained by increased 
production of or sensitivity to insulin, nor by increased levels of 
osteocalcin, they instead correlated significantly with increased 
skeletal uptake of glucose from the circulation, as evidenced by in 
vivo 18F-FDG tracer experiments. While glucose uptake was overall 
increased in bones of the mutant mice, 18F-FDG levels were normal 
in the majority of soft tissues (such as liver, spleen, lungs, heart, 
stomach, and skeletal muscle, as determined in resting condi-
tions, under general anesthesia [see Supplemental Table 1]). Strik-
ingly, already in a basal (WT) setting, the skeleton presented as a 
major contributor to the body’s glucose consumption, accounting 
for almost 15% of the glucose uptake from the blood in anesthe-
tized mice. This uptake is similar to or even higher than that seen 
in some of the established glucose-avid tissues such as heart, liv-
er, and brain, a finding that is in line with other recent work (30). 
Plausible explanations are the large total contribution of the skel-
humans (3, 28, 29). Osteocalcin–/– mice show an obese phenotype 
with hyperglycemia, hypoinsulinemia, and reduced insulin secre-
tion and sensitivity compared with WT mice (3). The reduced 
insulin sensitivity of the constitutive Vhl cKO mice may thus possi-
bly be explained through the endocrine actions of osteocalcin, but 
certainly not their hypoglycemic and lean phenotype. In fact, the 
low blood glucose levels in both our Vhl-deficient mouse models 
would be expected to lower insulin production and increase insu-
lin sensitivity; yet these responses were not seen, suggesting that 
counteracting mechanisms may have been operating to increase 
insulin production and reduce insulin sensitivity. Low osteocalcin 
would be expected to reduce insulin sensitivity (3), which could 
reflect a contribution of the low osteocalcin levels to the global 
metabolic phenotypes. With regard to the insulin levels, however, 
low osteocalcin cannot provide such a counteracting mechanism, 
as low osteocalcin is itself associated with reduced insulin produc-
tion and secretion. The reasons underlying the aberrantly normal 
insulin levels in these hypoglycemic mice thus remain enigmatic.
Given that the alterations in global glucose homeostasis in 
mice with Vhl inactivation could not be simply explained through 
the known endocrine actions of insulin or osteocalcin, our find-
Figure 11. Schematic summary. Left: Vhl inactivation in osteoprogenitors and the osteoblast lineage cells derived from them locally leads to excessive 
HIF stabilization and transcriptional activity, including strong upregulation of glucose transporters (Glut1) and glycolysis-promoting enzymes (Pgk1, 
Pdk1). These molecular changes are associated with increased glucose uptake and glycolysis in the Vhl-deficient osteolineage cells, and increased glucose 
consumption by the skeleton as a whole. Right: Systemically, Vhl cKO mice showed consistently reduced blood glucose levels and an increased glucose tol-
erance that could not be explained through effects on insulin or osteocalcin. Link between local and systemic phenotypes: Since systemic administration 
of the glycolysis inhibitor DCA rescued the metabolic phenotype, it is possible that the low glycemia was a direct consequence of the increased uptake of 
glucose in bone, although potential contributions by unknown endocrine-acting osteokines (osteocrine signals) cannot at present be excluded. These new 
findings strongly suggest that local glucose utilization in the skeleton contributes to systemic glucose clearance and metabolic homeostasis, a concept 
that may help in the development of therapies beneficial for both bone and metabolic health.
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mice, by rescuing specifically the whole-body metabolic imbal-
ance while having no discernible impact on the local bone mani-
festations, may argue against a critical role of endocrine signals 
emanating from the anomalous bone but in favor of a direct mech-
anism. Possibly in line with this hypothesis, mice overexpress-
ing GLUT1 in osteoblasts showed systemic metabolic alterations 
similarly including increased glucose tolerance, although high 
circulating osteocalcin levels could also explain the phenotype in 
this model (18). This may also predict that, conversely, a signifi-
cant reduction in osteoblast number or a deficiency in osteoblastic 
glucose uptake may be associated with reduced skeletal glucose 
utilization and impaired systemic glucose disposal. In this regard, 
it is interesting to note that mouse models of osteoblast ablation 
or of osteoblast-specific deletion of GLUT1 or GLUT4 were all 
associated with reduced glucose clearance and/or hyperglycemia, 
although these phenotypes were complex and often attributable at 
least in part to osteocalcin (6, 18, 19).
Combined VHL/HIF downstream effectors mediate the high-
bone-mass phenotype in mice lacking Vhl in osteolineage cells. Our 
data indicate that skeletal-specific Vhl cKO mice have high bone 
mass and a disrupted BM microenvironment that is heavily vas-
cularized with dilated blood vessels. Surprisingly, the bone forma-
tion and mineralization rate was greatly decreased at 12 weeks of 
age, associated with impaired terminal differentiation of osteo-
blasts and an expansion of the pool of relatively immature oste-
olineage cells depositing disorganized, woven bone matrix. No 
major alterations could be detected in the number of osteoclasts; 
however, the presence of aberrant cartilage remnants within the 
trabecular bone strongly suggests impaired osteoclast function-
ing. Inefficient resorption of the matrix could be caused by osteo-
clastic alterations or, alternatively, by anomalous modifications of 
the matrix rendering it more resistant to degradation. The latter 
could result, for instance, from alterations in the biosynthesis of 
collagens in chondrocytes and osteolineage cells, as HIF signaling 
is known to improve the efficiency of posttranslational hydroxyl-
ation of collagens and collagen crosslinking, thereby determining 
the conformational stability of collagen triple helices (10, 36, 37). 
The low bone turnover state at adult ages in Vhl-deficient mice 
indicates that increased bone matrix deposition and mineraliza-
tion must have occurred at earlier stages in life, similar to the 
findings made upon Ocn-Cre–driven Vhl inactivation, targeting 
mature osteoblasts (11). These mice showed increased bone for-
mation at 7 days of age, followed by a decline in bone turnover 
associated with progressively increased bone mass (11).
Intriguingly, DCA treatment revealed that blocking glycolysis 
only reversed the low glycemia and increased glucose tolerance, 
but not the augmented bone mass of Vhl mutants. In other words, 
the local effect on bone mass and the systemic effects on energy 
metabolism could be uncoupled by DCA-mediated inhibition of 
glycolysis. This finding indicates that, on the one hand, the con-
trol of glucose homeostasis by osteoblast lineage cells is not a bona 
fide consequence of the high bone mass (as discussed above), and 
on the other hand, the high bone mass does not rely solely on the 
enhanced glycolysis. This latter aspect can be reconciled with the 
findings by Regan et al. (21), who found that DCA did restore the 
increased bone mass of mice conditionally expressing a stabilized 
form of HIF-1α, by the fact that Vhl deletion also stabilizes HIF-2α, 
eton to the body and the high energetic demands associated with 
bone formation and maintenance. In accordance with this latter 
notion, we found that within bone, the most marked glucose-avid 
cell types were those residing on and in proximity of the trabecular 
and cortical bone surfaces, corresponding to osteoprogenitors and 
osteoblasts by location and morphology. Osteocytes appeared to 
contribute little to glucose consumption in murine bones.
Osteolineage cells thus appear responsible for a great deal of 
the skeletal glucose consumption. Early in vitro work indicated 
that osteogenic cells are highly glycolytic (31, 32). Recent in vivo 
studies provided evidence that glucose uptake in osteoblasts 
stands partly under the control of insulin, is mediated via GLUT1 
and GLUT4, and is crucial for osteoblast differentiation and 
bone formation (18, 19). Our data now provide in vivo evidence 
that increased utilization of glucose by osteoblasts, such as insti-
gated by genetic activation of HIF signaling, can put substantial 
pressure on global glucose homeostasis. Notably, the number of 
osteolineage cells in the body, taken cumulatively in the more 
than 200 bones constituting the skeleton, is likely considerable. 
In this light, it seems plausible that drastic changes in their glu-
cose consumption could have repercussions on overall systemic 
glucose homeostasis. Vhl deletion greatly increased the glycolytic 
flux and glucose utilization by osteogenic cells in vitro and in vivo. 
Such a shift in the use of glucose as a source of energy from oxida-
tive phosphorylation toward its breakdown via glycolysis, accom-
panied by increased glucose uptake to maintain energy demands 
(ATP production), resembles the Warburg effect that typifies can-
cer cells (13–15). Interestingly, the experimental anticancer drug 
and glycolysis inhibitor DCA corrected, at least partly, the bioen-
ergetic switch and increased glucose consumption of Vhl-deficient 
osteolineage cells, and prevented the global metabolic phenotype. 
Thus, osteolineage cells are largely responsible for the high skel-
etal demand of glucose, and inducing a state of hyper-Warburgism 
in these cells can increase the local glycolytic flux and glucose uti-
lization, apparently even to such an extent that it affects the over-
all glucose clearance from the circulation (Figure 11).
It thus seems that a continual drain of glucose toward the skel-
eton (as is possibly the case for other tissues) is able to cause an 
uncompensated imbalance in global glucose homeostasis, leading 
to an altered overall energy metabolism and even a failure to build 
up or a depletion of the body’s energy stores. The potential far-
reaching therapeutic implications of this concept are reinforced 
by our finding that patients carrying glucose-avid bone meta-
static tumor masses also showed an inverse correlation between 
the local glucose uptake in the cancer lesions and global glycemia 
levels. This observation opens an avenue of potential significance 
in tumor diagnosis, management, and treatment, warranting fur-
ther investigation. Notable in this regard, for instance, is the rare 
but documented occurrence of clinically asymptomatic hypogly-
cemia and lactic acidosis in certain nonpancreatic malignancies, 
especially lymphomas, which has been attributed to an extreme 
manifestation of the Warburg effect (33–35).
Possibly, a rewired osteoblastic metabolism may be able to 
influence systemic glucose clearance directly, although involve-
ment of secondary osteocrine signals cannot be excluded (Figure 
11). Yet the finding that DCA could uncouple the high-bone-mass 
phenotype from the increased glucose tolerance in PN–Vhl cKO 
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Methods
Animals. Osx-Cre:GFP mice (24) were crossed with Vhl floxed mice 
(25) in a mixed genetic background, as detailed in Supplemental Meth-
ods. For suppression of Vhl inactivation, doxycycline (Sigma-Aldrich) 
was added to the drinking water at 1 mg/ml and refreshed 3 times a 
week from conception until P21. Next, mice were randomly assigned 
to DCA (Sigma-Aldrich) or vehicle treatment groups; DCA was admin-
istered from 3 until 24 weeks of age (2 mg/ml drinking water).
Micro-CT. We used the in vivo Skyscan 1076 micro-CT system 
(Bruker) with scanning parameters 50 kV, 100 μA, and 9-μm voxel 
size, and applied a 1-mm aluminum filter. Postmortem micro-CT 
scans of tibias and vertebrae were made using the ex vivo Skyscan 
1172 device (Bruker) at 50 kV, 200 μA, 5-μm voxel size, and a 0.5-mm 
aluminum filter. Scans were reconstructed and analyzed using NRe-
con, CTAn, and CTVol software (Bruker), according to standardized 
protocols as detailed in Supplemental Methods.
Histology, IHC, and histomorphometry. Bones and soft tissues were 
processed for histology and stained as previously described (40, 41). 
IHC for PECAM-1/CD31 (BD Biosciences, catalog 550274) on paraf-
fin sections was as previously described (43). For costaining with GFP 
antibodies (chicken anti-GFP, 10 μg/ml, Abcam, ab13970), frozen sec-
tions were used; the PECAM-1 signal was amplified using fluorescein-
tyramide according to the TSA Cyanine 3 System (PerkinElmer) and 
GFP was detected using a secondary goat anti-chicken antibody (5 
μg/ml, Abcam, ab96951). Paraffin sections were reacted for periodic 
acid–Schiff (PAS) or reticulin using commercial kits (Sigma-Aldrich). 
For GLUT-1 IHC, we used rabbit anti-mouse primary antibodies (Mil-
liporeSigma, 07-1401) at 2.5 μg/ml and goat–anti-rabbit polyclonal 
secondary antibodies (Abcam, ab6720) at 5 μg/ml. Insulin IHC was 
performed as described in Supplemental Methods. Images were taken 
with an Olympus IX83 inverted microscope equipped with DP73 cam-
era. Histomorphometry was performed as previously described (44) 
and as detailed in Supplemental Methods.
Cell culture studies. Primary osteoblasts were isolated from long 
bones of 12-week-old Vhlfl/fl mice by enzymatic digestion as outlined 
in Supplemental Methods, combining the yield from 3 mice to obtain 1 
independent cell pool. Each cell pool was split into a pair of an experi-
mental and a control sample, transduced respectively with adenoviruses 
encoding Cre (AdCre) or carrying a GFP-expressing or empty vector 
(AdGFP/AdEmpty; Viral Vector Core, University of Iowa; see Supple-
mental Methods). Glucose and lactate levels were measured in the 
conditioned medium. Glucose uptake in the cells was determined by 
adding 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose 
(2-NBDG; ThermoFisher Scientific) to the medium at 100 μM for 8 hours 
and measuring fluorescence at 485/540 nm. ATP production was quan-
tified using the ATPLite kit (PerkinElmer). Extracellular flux analysis was 
performed on a Seahorse Bioscience XFp analyzer (Agilent), measuring 
OCR and ECAR during baseline conditions and after addition of mito-
chondrial stress test components (1 μM oligomycin, 1 μM FCCP, 0.5 μM 
rotenone) or DCA (50 mM; MilliporeSigma). Results were normalized 
for DNA content of the corresponding culture well. In vitro osteogenic 
differentiation was performed as previously described (44).
Gene expression analysis. Western blot and real-time quantitative 
RT-PCR were performed as described in Supplemental Methods, 
using the primers and probes detailed in Supplemental Table 4. Rela-
tive mRNA levels were calculated by the ΔΔCt method, using Hprt as 
housekeeping gene.
as well as other less-well-characterized factors (26). The repercus-
sions of enhanced signaling by HIF-1α versus HIF-2α were recent-
ly studied in models of Osx-Cre:GFP–driven overexpression of the 
respective HIFs (38), confirming and extending earlier studies 
indicating that the genes regulated by HIF-1α and HIF-2α in osteo-
blasts are overlapping but nonidentical. While HIF-1α appears to 
be primarily responsible for meditating the metabolic switch to 
glycolysis, VEGF upregulation in osteogenic cells is controlled 
by both HIF-1α and HIF-2α (10, 21, 38). Additionally, HIF-2α has 
been shown to be the main regulator for EPO production by osteo-
blasts (12) and to regulate OPG, the factor that inhibits osteoclas-
togenesis by counteracting RANKL (38). All of these downstream 
effectors of the VHL/HIF axis — whose increased expression fully 
correlated with the presence of the local bone phenotype in our 
Vhl-deficient models, including in being unaffected by DCA treat-
ment — could have contributed to or caused the high bone mass 
and BM alterations. First, VEGF represents a key player in the tight 
coupling of angiogenesis and osteogenesis. Several studies have 
shown that inhibiting or increasing angiogenesis by modulation of 
VEGF expression decreases or stimulates bone formation, respec-
tively (10, 39–41). Overall, the bone phenotype described here in 
Vhl cKO mice resembles in many respects the phenotype associ-
ated with induced VEGF overexpression in the osteochondro-
lineage cells of adult mouse bones, including the observed hyper-
vascularization, BM fibrosis, and unbalanced bone formation 
and turnover (41). This suggests that increased VEGF expression 
by VHL-deficient osteoblasts, and consequent VEGF-mediated 
angiogenic-osteogenic coupling, constitutes a prime contribu-
tor to the local bone alterations in Vhl cKO mice. Second, besides 
regulating erythropoiesis, EPO has also been shown to stimulate 
bone formation and repair (42). Third, OPG has been recognized 
as a direct transcriptional target of HIF-2α, and at least part of the 
net bone anabolic effect of HIF-2α has been ascribed to reduced 
bone resorption (38).
Altogether, our data on 2 models of Vhl deletion, in light of the 
available knowledge and published work, suggest that the changes 
in systemic energy metabolism are a consequence of increased 
osteolineage cell glycolysis and bone glucose uptake, whereas the 
high bone mass is presumably due to a combination of mecha-
nisms, including — possibly among others — increased skel-
etal vascularization and altered angiogenic-osteogenic coupling, 
excessive glycolytic pathway activation in osteolineage cells, 
increased activity of early osteolineage cells with unbalanced 
bone formation and mineralization, and reduced bone resorption. 
These combined effects are mediated by dysregulation of various 
genes downstream of both HIF-1α and HIF-2α.
In conclusion, this study reveals that cellular glucose utilization 
by osteoblasts may represent an important determinant of global 
glucose homeostasis, with the capacity to override the established 
endocrine mechanisms involving the osteocalcin-insulin axis. This 
new link between bone and systemic energy metabolism may be 
direct, or act via as-yet-uncharacterized osteocrine factors, and 
stands under the control of the hypoxia signaling pathway in osteo-
lineage cells (Figure 11). These findings may have implications for 
the future use of bone anabolic therapies for osteoporosis, particu-
larly regarding their potential interplay with metabolic homeosta-
sis and disorders such as obesity and diabetes mellitus.
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Study approval. The animal experiments were in accordance with 
the institutional authorities’ guidelines and formally approved by the 
Animal Ethics Committee of the KU Leuven. The POUMOS-TEC 
cohort was approved by the local ethics committee (CPP Sud Est IV, 
Lyon, France) and registered into ClinicalTrials.gov under the ID 
NCT02810262. Patients provided written informed consent.
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Metabolic studies and bioassays. For GTT and GSIS, glucose was 
injected i.p. after overnight fasting, at 2 g/kg BW and 3 g/kg BW, 
respectively. For ITT, mice were fasted for 3 hours and injected i.p. 
with 0.75 U/kg BW insulin. Blood glucose was measured using a One-
Touch Verio glucose monitor (LifeScan). ELISA assays were used to 
determine serum insulin, leptin, adiponectin (all from Crystal Chem), 
osteocalcin (Immunotopics), CTX, and P1NP (both from Immuno-
Diagnostic Systems). Indirect calorimetry was done as described in 
Supplemental Methods.
Radioactive glucose tracing. 18F-FDG biodistribution assays and 
micro-PET imaging were performed in the KU Leuven molecular 
Small Animal Imaging Centre (moSAIC). 18F-FDG was prepared 
through an Ion Beam Applications synthesis module. After overnight 
fasting, 10- to 12-week-old mice were anesthetized with isoflurane 
inhalation before tail vein injection with 18F-FDG (doses given in μCi = 
BW×16). Mice were sacrificed 45 minutes later, or subjected to small-
animal PET imaging for 60 minutes using a lutetium oxyorthosilicate 
detector–based FOCUS 220 tomograph (Siemens/Concorde Micro-
systems). Time-activity curves were made using PMODv.3.1 software 
(PMOD Technologies LLC). For details, see Supplemental Methods.
Fluorescent glucose tracing experiments. Eight-week-old anesthe-
tized mice were injected with 25 mg/kg BW of 2-NBDG via the tail 
vein, and sacrificed 5 or 45 minutes after injection. Tissues were fixed 
with 4% paraformaldehyde at 4°C for 4 hours. Calvaria were imaged 
whole-mount using a MZ165 stereomicroscope (Leica). Tibias were 
decalcified for 2 weeks in 0.5 M EDTA, embedded in freezing medium 
(Freeze Gel Q Path, VWR), sectioned, and analyzed and imaged using 
an Olympus IX83 microscope.
Human data. We investigated data from 10 patients from the 
noninterventional, prospective POUMOS-TEC cohort that includes 
patients presenting with first bone metastases from adenocarcinoma 
lung cancer (stage IV) (27). As detailed in Supplemental Methods, 
serum biochemical parameters and FDG SUV parameters for each 
bone metastatic lesion observed by 18F-FDG PET/CT scans were 
determined. Correlations were computed and assessed using 2-tailed 
nonparametric tests.
Statistics. All data are presented as mean ± SEM. Comparisons 
between 2 groups were done by 2-tailed Student’s t tests. For multi-
ple comparisons between groups, we performed 2-way ANOVA with 
Bonferroni post hoc tests (GraphPad Prism 5). Correlations were com-
puted and assessed using Pearson correlation coefficient tests. For the 
human data, correlations were computed by nonparametric Spearman 
correlation coefficient tests. Throughout the study, P values below 
0.05 were considered significant.
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